Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,137.90
(
1.05%
)
US TECH 100
26,234.02
(
1.79%
)
Dow Jones
49,490.03
(
0.09%
)
Brent Oil
96.76
(
1.84%
)
Bitcoin
78,616.46
(
3.00%
)
News Focus
News Focus
Post# of 517490
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

frrol

Send PM Follow Ignore
Followers 96
Posts 12246
Boards Moderated 0
Alias Born 06/06/2014

frrol

Re: falconer66a post# 300966

Sunday, 02/28/2021 12:02:26 AM

Sunday, February 28, 2021 12:02:26 AM

Post# of 517490
The 2016 FMR1 study with 2-73 was very promising, and I'm looking forward to our Fragile X clinical trial. It's clearly worth pursuing, especially with our Rett outcomes coming in strong.

The recent S1 chromatin modulation function might indeed be the key, and explain and support the 2016 study. The company is clearly excited even more now to test in the clinic.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AVXL News
More AVXL News